Investigational drug · Phase 2
SGC001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Anterior ST-Segment Elevation Myocardial Infarction, Acute Pancreatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "SGC001"
First trial start
2026
Mar 9, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SGC001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Anterior ST-Segment Elevation Myocardial Infarction
- Acute Pancreatitis
Approved drugs for the same conditions: Coronary artery disease and heart attack · Cardiovascular and metabolic · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SGC001" as an intervention, largest first.
- A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial InfarctionPivotal-lookingRecruiting
Beijing Sungen Biomedical Technology Co., LtdIndustry
NCT07306182 · 210 participants (planned) · Start Mar 9, 2026 · Primary completion Apr 2027
Drug: SGC001 injection; SGC001 injection and 1 more · For: Acute Anterior ST-Segment Elevation Myocardial Infarction
Sites: Shanghai, China
- Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary EfficacyPivotal-lookingRecruiting
Beijing Sungen Biomedical Technology Co., LtdIndustry
NCT07803965 · 129 participants (planned) · Start Sep 30, 2026 · Primary completion Nov 2027
Drug: SGC001 injection; Placebo · For: Acute Pancreatitis
Sites: Chengdu, China; Guizhou, China; Hangzhou, China · 15 sites in all
Beijing Sungen Biomedical Technology Co., LtdIndustry
NCT07079618 · 49 participants · Start Aug 20, 2024 · Primary completion Jul 15, 2025
Drug: SGC001; Placebo · For: Anterior Myocardial Infarction
Sites: Beijing, China
Beijing Sungen Biomedical Technology Co., LtdIndustry
NCT07091929 · 38 participants · Start Jan 20, 2025 · Primary completion Jul 18, 2025
Drug: SGC001; Placebo · For: Anterior Myocardial Infarction
Sites: Beijing, China; Harbin, China; Linfen, China · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.